Enceladus Bio

Ownership

Private

Employees

~50

Stage

Preclinical

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Modalities

CRISPRgenome editing

Enceladus Bio General Information

Enceladus Bio is developing next-generation genetic medicines using CRISPR and genome editing. No public clinical results are available yet.

Contact Information

Website

https://www.linkedin.com/company/enceladusbio

Primary Industry

Biotech

Corporate Office

New York, NY
USA

Drug Pipeline

No pipeline data available

For full access to Enceladus Bio's pipeline data

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Enceladus Bio Funding

No funding data available

Early Stage VC (Series A)	04-Jun-2020	$38M	Completed	Phase 1
Seed Round	12-Feb-2019	$8.5M	Completed	Startup

Interested in comprehensive profile data?

We'll help you find what you need

To view Enceladus Bio's complete valuation and funding history, request access »

Enceladus Bio Financial Metrics